Cargando…
Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
Mutation of the BRAF proto-oncogene is found in approximately 10% of colorectal cancers (CRC), with much of the mutation conferred by a V600E mutation. Unlike other CRC subtypes, BRAF-mutant CRC have had relatively limited response to conventional therapies and overall poor survival. We present the...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716546/ https://www.ncbi.nlm.nih.gov/pubmed/34975492 http://dx.doi.org/10.3389/fphar.2021.795381 |